Microbix & Seegene Mexico Collaborate to Improve Test Accuracy

(TSX:MBX),(OTC US:MBXBF),(Other OTC:MBXBF), MISSISSAUGA, Ontario and MEXICO CITY, Dec. 03, 2025 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix(R)), a life sciences innovator, manufacturer, and exporter, and Seegene Mexico S.A.P.I. de C.V. (Seegene Mexico), a firm focused upon transforming molecular diagnostics with innovative multiplex solutions, announce that Microbix external third-party quality assessment […]

Iolyx Therapeutics Enters Strategic Agreement with Laboratoires Thea to Develop and Commercialize ILYX-002 intended for the Treatment of Autoimmune Associated Dry Eye Disease and Secures Series B Funding for Retinal Pipeline

Deal with Laboratoires Thea representing a total value of up to $280 million including clinical, regulatory and commercial conditional milestones, commercial royalties, and development responsibility for Phase 3 trials Funds from concurrent Series B financing to support expansion of pipeline including retinal diseases BURLINGAME, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) — Iolyx Therapeutics, a clinical-stage

ARTHUR CAPITAL INC. Concludes Share Buyback Program at $4.00/Share

WILMINGTON, Dec. 03, 2025 (GLOBE NEWSWIRE) — ARTHUR CAPITAL INC. is pleased to announce the conclusion of its share buyback program at $4.00/share. Repurchases were made through privately negotiated transactions and shares were subsequently canceled. About ARTHUR CAPITAL INC. offers high-octane Interim CFO Services for special situations (Private Equity — Turnarounds — Workouts — Bankruptcies

Carlsmed Announces U.S. Launch of its aprevo(R) Technology Platform for Cervical Fusion Surgeries at the Cervical Spine Research Society (CSRS) 53rd Annual Meeting

(NASDAQ:CARL), CARLSBAD, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) — Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the U.S. commercial launch of its aprevo(R) Technology Platform for cervical fusion surgeries. Surgeons involved in the clinical evaluation will also present early clinical data at the Cervical Spine Research Society (CSRS) 53rd Annual Meeting in

Emerita Awards Pre-Feasibility Study Contract for the Iberian Belt West Project to SLR Consulting

(TSX-V:EMO),(OTC US:EMOTF),(Other OTC:EMOTF),(Frankfurt:LLJA), TORONTO, Dec. 03, 2025 (GLOBE NEWSWIRE) — Emerita Resources Corp. (TSX – V: EMO; OTCQB: EMOTF; FSE: LLJA) (the “Company” or “Emerita“) is pleased to announce it has awarded the contract for completion of the Iberian Belt West (IBW) Pre-Feasibility Study (PFS) to SLR Consulting Limited (formerly Wardell Armstrong) (“SLR“). The PFS

Mythics Accelerates Oracle Multi-Cloud Momentum, Driving Transformation Across Leading Hyperscalers

Through deep Oracle expertise and strategic hyperscaler partnerships, Mythics is helping enterprises unlock agility, scalability, and cost efficiency in their multi-cloud transformations. Mythics, a leading Oracle systems integrator and cloud solutions provider, announced expanded capabilities supporting Oracle's multi-cloud strategy to accelerate innovation by deploying OCI's Oracle AI Database services in all majorhyperscaler platforms, including Google

Moomoo Partners with OTC Markets’ MOON ATS(R) to Expand Its 24-Hour Trading for Retail Investors

(Other OTC:OTCM),(OTC US:OTCM), NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for more than 12,000 U.S. and global securities, and Moomoo, a leading global investment and trading platform with over 28 million global users, today announced a major achievement in retail investing. Moomoo officially connected

Larkspur Biosciences Begins Dosing in Clinical Study of LRK-4189, a First-in-Class Targeted Protein Degrader

LRK-4189, which targets PIP4K2C, a key cancer cell fitness target, is being developed for microsatellite stable (MSS) colorectal cancer (CRC) and other solid tumors Clinical study begins with healthy participants to establish early tolerability, pharmacokinetics, and pharmacodynamics CAMBRIDGE, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) — Larkspur Biosciences, a company pioneering a new wave in cancer

GRIN Therapeutics to Present on Global Phase 3 Beeline Clinical Trial of Radiprodil at American Epilepsy Society Annual Meeting

Presentation highlights novel methodologies for measuring clinical outcomes, including seizure frequency and behavioral changes, in currently recruiting Phase 3 study in GRIN-relatedneurodevelopmental disorder (GRIN-NDD) GRIN Therapeutics, Inc., a leader in the development of targeted disease-specific therapies to treat serious neurodevelopmental disorders, today announced that it will presentinsights on the development of novel rating scales for

Axon Vision Announce Strategic Cooperation Agreement with Leonardo DRS to Deliver AI-Enhanced Counter-UAS Solutions for U.S. Market

Axon Vision (TASE: AXN) announced today a strategic cooperation agreement with Leonardo DRS to pursue opportunities in advanced situational awareness, lethality, and survivability, with special emphasis on Counter-UAS (C-UAS) solutions in the U.S. defense market. The partnership is expected to address a critical demand for on-platform AI-driven capabilities that support force protection and platform modernization.

Scroll to Top